These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3139316)

  • 1. Pharmacokinetics of thio-TEPA at two different doses.
    Hagen B; Walstad RA; Nilsen OG
    Cancer Chemother Pharmacol; 1988; 22(4):356-8. PubMed ID: 3139316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.
    Hagen B; Neverdal G; Walstad RA; Nilsen OG
    Cancer Chemother Pharmacol; 1990; 25(4):257-62. PubMed ID: 1688514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.
    Hagen B
    Cancer Chemother Pharmacol; 1991; 27(5):373-8. PubMed ID: 1705489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma.
    Hagen B; Walseth F; Walstad RA; Iversen T; Nilsen OG
    Cancer Chemother Pharmacol; 1987; 19(2):143-8. PubMed ID: 3105905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Br J Clin Pharmacol; 2001 Jan; 51(1):61-70. PubMed ID: 11167666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
    Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
    Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.
    Langer CJ; Nash S; Catalano R; Rosenblum NG; Hogan WM; Comis RL; O'Dwyer PJ
    Gynecol Oncol; 1991 Dec; 43(3):242-6. PubMed ID: 1752494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.
    Ng SF; Waxman DJ
    Cancer Res; 1991 May; 51(9):2340-5. PubMed ID: 1707751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/pharmacokinetic reevaluation of thioTEPA.
    O'Dwyer PJ; LaCreta F; Engstrom PF; Peter R; Tartaglia L; Cole D; Litwin S; DeVito J; Poplack D; DeLap RJ
    Cancer Res; 1991 Jun; 51(12):3171-6. PubMed ID: 1710167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 32p-labeled thio-tepa absorption in normal rat bladders: potential guide for intravesical chemotherapy in bladder cancer.
    Puchner PJ; Veenema RJ; Tomashefsky P; Pinzus T; Tannenbaum T
    Urology; 1974 Jul; 4(1):33-6. PubMed ID: 21322979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
    Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2001 Dec; 23(6):650-7. PubMed ID: 11802099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of Thio-TEPA on advanced ovarian cancer (author's transl)].
    Luciani L; De Palo GM; Conti U; Mattavelli F; Di Re F
    Tumori; 1973; 59(4):259-67. PubMed ID: 4357004
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chromosomal aberrations induced by thio-TEPA in cells of malignant ovarian tumors in humans].
    Neĭshtadt EL; Gnilevskaia ZU; Aĭnbinder NM
    Vopr Onkol; 1975; 21(7):48-53. PubMed ID: 814712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.
    Hagen B; Dale O; Neverdal G; Azri S; Nilsen OG
    Cancer Chemother Pharmacol; 1991; 28(6):441-7. PubMed ID: 1718615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.
    Masters JR; McDermott BJ; Harland S; Bibby MC; Loadman PM
    Cancer Chemother Pharmacol; 1996; 38(1):59-64. PubMed ID: 8603453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mitotic activity in ovarian serous cystadenocarcinomas treated with thio-TEPA].
    Irzhanov SI
    Akush Ginekol (Mosk); 1979 Dec; (12):38-9. PubMed ID: 119443
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
    Sandles LG; Freedman RS; Raber MN; Kavanagh J; Edwards CL; Scott WR; Wharton JT
    Gynecol Oncol; 1990 Nov; 39(2):139-45. PubMed ID: 2121628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacology of N,N',N''-triethylene thiophosphoramide.
    Miller B; Tenenholz T; Egorin MJ; Sosnovsky G; Rao NU; Gutierrez PL
    Cancer Lett; 1988 Aug; 41(2):157-68. PubMed ID: 3135933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.